SK Holdings leads SG's Hummingbird Bioscience's $25m Series B extension

SK Holdings leads SG's Hummingbird Bioscience's $25m Series B extension

Antibody visual sourced from Hummingbird's website

Singapore-based cancer antibody developer Hummingbird Bioscience has closed an extended Series B round at $25 million led by South Korean conglomerate SK Holdings.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter